Egalet Stock Price, News & Analysis (NASDAQ:EGLT)

$0.76 -0.04 (-5.00 %)
(As of 02/22/2018 05:36 AM ET)
Previous Close$0.81
Today's Range$0.75 - $0.81
52-Week Range$0.75 - $5.60
Volume446,500 shs
Average Volume868,894 shs
Market Capitalization$36.99 million
P/E RatioN/A
Dividend YieldN/A
Beta0.37

About Egalet (NASDAQ:EGLT)

Egalet logoEgalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Receive EGLT News and Ratings via Email

Sign-up to receive the latest news and ratings for EGLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EGLT
CUSIPN/A
Phone610-833-4200

Debt

Debt-to-Equity Ratio-3.43%
Current Ratio2.73%
Quick Ratio2.68%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.96 million
Price / Sales2.06
Cash FlowN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book3.62

Profitability

Trailing EPS($3.39)
Net Income$-90,630,000.00
Net Margins-376.62%
Return on EquityN/A
Return on Assets-73.83%

Miscellaneous

Employees154
Outstanding Shares45,940,000

Egalet (NASDAQ:EGLT) Frequently Asked Questions

What is Egalet's stock symbol?

Egalet trades on the NASDAQ under the ticker symbol "EGLT."

How were Egalet's earnings last quarter?

Egalet Corp (NASDAQ:EGLT) released its quarterly earnings data on Thursday, August, 4th. The specialty pharmaceutical company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.15. The specialty pharmaceutical company had revenue of $3.45 million for the quarter, compared to the consensus estimate of $3.83 million. The company's revenue for the quarter was up 259.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.03) EPS. View Egalet's Earnings History.

When will Egalet make its next earnings announcement?

Egalet is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Egalet.

Where is Egalet's stock going? Where will Egalet's stock price be in 2018?

5 brokerages have issued 1-year price objectives for Egalet's stock. Their predictions range from $1.50 to $9.50. On average, they anticipate Egalet's share price to reach $6.20 in the next year. View Analyst Ratings for Egalet.

Who are some of Egalet's key competitors?

Who are Egalet's key executives?

Egalet's management team includes the folowing people:

  • Timothy P. Walbert, Independent Chairman of the Board (Age 50)
  • Robert Radie, President, Chief Executive Officer, Director (Age 52)
  • Stanley J. Musial, Chief Financial Officer, Executive Vice President, Secretary (Age 55)
  • Mark Strobeck Ph.D., Chief Operating Officer, Executive Vice President (Age 45)
  • Paul C. Varki J.D., Senior Vice President, General Counsel
  • E. Blair Clark-Schoeb, Senior Vice President - Communications
  • Karsten Lindhardt Ph.D., Senior Vice President - Research & Development (Age 44)
  • Barbara Carlin, Chief Accounting Officer (Age 41)
  • Jeffrey M. Dayno M.D., Chief Medical Officer (Age 59)
  • Patrick M. Shea, Chief Commercial Officer

Who owns Egalet stock?

Egalet's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.57%). Company insiders that own Egalet stock include Deanne F Melloy, Jeffrey M Dayno, Mark Strobeck, Patrick M Shea, Paul Varki, Robert S Radie and Stan Musial. View Institutional Ownership Trends for Egalet.

Who bought Egalet stock? Who is buying Egalet stock?

Egalet's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Egalet.

How do I buy Egalet stock?

Shares of Egalet can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Egalet's stock price today?

One share of Egalet stock can currently be purchased for approximately $0.76.

How big of a company is Egalet?

Egalet has a market capitalization of $36.99 million and generates $16.96 million in revenue each year. The specialty pharmaceutical company earns $-90,630,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis. Egalet employs 154 workers across the globe.

How can I contact Egalet?

Egalet's mailing address is 600 LEE ROAD SUITE 100, WAYNE PA, 19087. The specialty pharmaceutical company can be reached via phone at 610-833-4200 or via email at [email protected]


MarketBeat Community Rating for Egalet (EGLT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  385
MarketBeat's community ratings are surveys of what our community members think about Egalet and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Egalet (NASDAQ:EGLT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.602.803.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.20$6.20$7.10$7.10
Price Target Upside: 501.94% upside501.94% upside755.42% upside517.39% upside

Egalet (NASDAQ:EGLT) Consensus Price Target History

Price Target History for Egalet (NASDAQ:EGLT)

Egalet (NASDAQ:EGLT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2018Stifel NicolausDowngradeBuy -> Hold$1.50HighView Rating Details
12/15/2017Cantor FitzgeraldSet Price TargetBuy$7.00HighView Rating Details
11/9/2017GabelliDowngradeBuy -> HoldN/AView Rating Details
8/14/2017GuggenheimSet Price TargetBuy$7.00HighView Rating Details
7/14/2017JMP SecuritiesLower Price TargetMarket Outperform$15.00 -> $6.00MediumView Rating Details
3/14/2016Janney Montgomery ScottInitiated CoverageNeutral$8.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Egalet (NASDAQ:EGLT) Earnings History and Estimates Chart

Earnings by Quarter for Egalet (NASDAQ:EGLT)

Egalet (NASDAQ EGLT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018        
11/8/2017Q3 2017($0.47)($0.46)$7.46 million$6.65 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.94)($1.04)$6.68 million$6.26 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.90)($1.02)$6.92 million$5.57 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.92)($0.87)$5.37 million$6.14 millionViewListenView Earnings Details
11/4/2016Q316($0.90)($1.10)$4.50 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($0.82)($0.97)$3.83 million$3.45 millionViewN/AView Earnings Details
5/10/2016Q116($0.87)($0.76)$3.50 million$2.70 millionViewListenView Earnings Details
3/8/2016Q415($0.91)($0.28)$2.80 million$2.10 millionViewN/AView Earnings Details
11/4/2015Q315($0.90)($0.81)$1.62 million$1.30 millionViewN/AView Earnings Details
8/6/2015Q215($1.02)($0.98)$0.95 million$0.96 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.98)($1.02)$3.00 million$0.81 millionViewN/AView Earnings Details
3/16/2015Q414($0.71)($0.52)$0.30 million$0.83 millionViewN/AView Earnings Details
11/12/2014Q314($0.75)($0.63)$0.35 millionViewN/AView Earnings Details
8/12/2014Q214($0.41)($0.73)$0.49 millionViewN/AView Earnings Details
5/13/2014Q114($0.16)($1.34)$0.26 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Egalet (NASDAQ:EGLT) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.81 EPS
Next Year EPS Consensus Estimate: $-1.26 EPS

Dividends

Dividend History for Egalet (NASDAQ:EGLT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Egalet (NASDAQ EGLT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 47.85%
Insider Trades by Quarter for Egalet (NASDAQ:EGLT)
Insider Trades by Quarter for Egalet (NASDAQ:EGLT)

Egalet (NASDAQ EGLT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Patrick M SheaInsiderSell910$1.00$910.0037,020View SEC Filing  
10/2/2017Mark StrobeckCOOSell8,700$1.29$11,223.0012,080View SEC Filing  
10/2/2017Patrick M SheaInsiderSell910$1.30$1,183.0037,930View SEC Filing  
7/3/2017Patrick M. SheaInsiderSell910$2.35$2,138.50View SEC Filing  
7/3/2017Paul VarkiSVPSell806$2.35$1,894.10View SEC Filing  
7/3/2017Stan MusialCFOSell3,480$2.36$8,212.8042,407View SEC Filing  
6/30/2017Mark StrobeckCOOSell8,700$2.39$20,793.0020,780View SEC Filing  
4/3/2017Paul VarkiSVPSell806$5.05$4,070.3028,820View SEC Filing  
4/3/2017Stan MusialCFOSell8,613$5.04$43,409.5245,887View SEC Filing  
3/31/2017Jeffrey M DaynoInsiderSell536$5.16$2,765.7618,212View SEC Filing  
3/31/2017Mark StrobeckCOOSell8,700$5.11$44,457.0029,480View SEC Filing  
3/20/2017Patrick M SheaInsiderSell4,250$4.75$20,187.5038,250View SEC Filing  
1/3/2017Jeffrey M DaynoInsiderSell536$7.75$4,154.0018,748View SEC Filing  
1/3/2017Paul VarkiSVPSell806$7.75$6,246.5029,626View SEC Filing  
1/3/2017Stan MusialCFOSell13,480$7.73$104,200.4054,500View SEC Filing  
12/30/2016Mark StrobeckCOOSell8,700$7.81$67,947.0038,180View SEC Filing  
10/3/2016Paul VarkiSVPSell806$7.56$6,093.3630,432View SEC Filing  
10/3/2016Robert S RadieInsiderSell15,000$7.47$112,050.00234,900View SEC Filing  
10/3/2016Stan MusialCFOSell13,480$7.47$100,695.6067,980View SEC Filing  
9/30/2016Jeffrey M DaynoInsiderSell536$7.69$4,121.8419,284View SEC Filing  
9/30/2016Mark StrobeckCOOSell33,700$7.58$255,446.0071,880View SEC Filing  
7/6/2016Robert S RadieCEOSell15,000$5.01$75,150.00259,900View SEC Filing  
7/5/2016Robert S RadieCEOSell5,000$4.94$24,700.00259,900View SEC Filing  
7/5/2016Stan MusialCFOSell13,480$5.06$68,208.8084,940View SEC Filing  
7/1/2016Robert S RadieCEOSell5,000$5.07$25,350.00259,900View SEC Filing  
7/1/2016Stan MusialCFOSell10,000$5.06$50,600.0084,940View SEC Filing  
6/30/2016Jeffrey M DaynoInsiderSell536$4.65$2,492.4019,820View SEC Filing  
4/5/2016Deanne F MelloyInsiderSell860$6.96$5,985.6033,420View SEC Filing  
4/5/2016Robert S RadieCEOSell5,000$6.99$34,950.00264,900View SEC Filing  
4/4/2016Robert S RadieCEOSell10,000$6.97$69,700.00274,900View SEC Filing  
1/11/2016Robert S. RadieCEOSell10,000$9.65$96,500.00279,900View SEC Filing  
1/6/2016Robert S. RadieCEOSell5,000$10.52$52,600.00298,900View SEC Filing  
10/6/2015Deanne F MelloyInsiderSell860$11.42$9,821.2035,140View SEC Filing  
10/1/2015Robert S RadieCEOSell15,000$12.27$184,050.00303,900View SEC Filing  
10/1/2015Stan MusialCFOSell8,480$12.32$104,473.60101,900View SEC Filing  
9/30/2015Mark StrobeckInsiderSell5,220$12.56$65,563.20106,680View SEC Filing  
7/8/2015Robert S RadieCEOSell6,000$11.97$71,820.00View SEC Filing  
7/6/2015Robert S RadieCEOSell9,000$12.53$112,770.00View SEC Filing  
7/1/2015Mark StrobeckInsiderSell10,440$12.98$135,511.20View SEC Filing  
7/1/2015Stan MusialCFOSell8,480$13.20$111,936.00View SEC Filing  
4/1/2015Robert S RadieCEOSell11,130$11.25$125,212.50View SEC Filing  
2/3/2015Jeffrey M DaynoInsiderSell2,500$8.87$22,175.00View SEC Filing  
1/2/2015Mark StrobeckInsiderSell3,480$5.09$17,713.20View SEC Filing  
1/2/2015Robert S RadieCEOSell11,130$5.11$56,874.30View SEC Filing  
9/10/2014Robert S RadieCEOSell40,040$9.61$384,784.40View SEC Filing  
9/8/2014Robert S RadieCEOSell49,000$9.74$477,260.00View SEC Filing  
8/13/2014Mark StrobeckInsiderSell5,135$9.20$47,242.00View SEC Filing  
8/11/2014Mark StrobeckInsiderSell5,700$10.28$58,596.00View SEC Filing  
8/7/2014Mark StrobeckInsiderSell3,085$11.50$35,477.50View SEC Filing  
8/7/2014Stan MusialCFOSell13,920$11.05$153,816.00View SEC Filing  
2/11/2014Jean Francois FormelaDirectorBuy41,667$12.00$500,004.00View SEC Filing  
2/11/2014Life Science Ventures SunstoneMajor ShareholderBuy133,333$12.00$1,599,996.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Egalet (NASDAQ EGLT) News Headlines

Source:
DateHeadline
$8.54 Million in Sales Expected for Egalet Corp (EGLT) This Quarter$8.54 Million in Sales Expected for Egalet Corp (EGLT) This Quarter
www.americanbankingnews.com - February 21 at 4:12 AM
Egalet (EGLT) Reports Issuance of New U.S. Patent for Guardian TechnologyEgalet (EGLT) Reports Issuance of New U.S. Patent for Guardian Technology
www.streetinsider.com - February 20 at 8:46 AM
Egalet Corp (EGLT) Receives Consensus Recommendation of "Hold" from BrokeragesEgalet Corp (EGLT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 10 at 3:24 AM
Egalet Corp (EGLT) Expected to Announce Quarterly Sales of $8.54 MillionEgalet Corp (EGLT) Expected to Announce Quarterly Sales of $8.54 Million
www.americanbankingnews.com - February 4 at 6:10 AM
Egalet Corp (EGLT) Expected to Post Earnings of -$0.38 Per ShareEgalet Corp (EGLT) Expected to Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - February 2 at 7:08 PM
Egalet to Participate in Panel at BIO CEO & Investor ConferenceEgalet to Participate in Panel at BIO CEO & Investor Conference
finance.yahoo.com - February 1 at 6:49 AM
Egalet (EGLT) Reports Online Publishing of ARYMO ER Data - StreetInsider.comEgalet (EGLT) Reports Online Publishing of ARYMO ER Data - StreetInsider.com
www.streetinsider.com - January 29 at 6:43 AM
Egalet Announces ARYMO® ER Data Published in Current Medical Research and Opinion JournalEgalet Announces ARYMO® ER Data Published in Current Medical Research and Opinion Journal
finance.yahoo.com - January 29 at 6:43 AM
Egalet to Co-Host Category 1 Focus GroupEgalet to Co-Host Category 1 Focus Group
www.prnewswire.com - January 24 at 6:43 AM
Egalets Partner OraPharma Begins Promotion of SPRIX® Nasal SprayEgalet's Partner OraPharma Begins Promotion of SPRIX® Nasal Spray
www.prnewswire.com - January 23 at 6:23 AM
 Brokerages Expect Egalet Corp (EGLT) Will Announce Earnings of -$0.38 Per Share Brokerages Expect Egalet Corp (EGLT) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - January 16 at 9:24 PM
Egalet Corp (EGLT) Given Average Recommendation of "Hold" by AnalystsEgalet Corp (EGLT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - January 16 at 3:38 AM
Egalet (EGLT) and Xenon Pharmaceuticals (XENE) Head-To-Head ComparisonEgalet (EGLT) and Xenon Pharmaceuticals (XENE) Head-To-Head Comparison
www.americanbankingnews.com - January 9 at 5:10 AM
Developments in the Biotech and Pain Management Therapeutics SegmentsDevelopments in the Biotech and Pain Management Therapeutics Segments
www.prnewswire.com - January 5 at 9:35 AM
Egalet (EGLT) Announces Partnership with OraPharma to Co ... - StreetInsider.comEgalet (EGLT) Announces Partnership with OraPharma to Co ... - StreetInsider.com
www.streetinsider.com - January 3 at 5:24 PM
Egalet targeting dentists in co-promotion deal with Montco firmEgalet targeting dentists in co-promotion deal with Montco firm
finance.yahoo.com - January 3 at 5:24 PM
Egalet (EGLT) Announces Partnership with OraPharma to Co-Promote SPRIX Nasal SprayEgalet (EGLT) Announces Partnership with OraPharma to Co-Promote SPRIX Nasal Spray
www.streetinsider.com - January 3 at 8:39 AM
Egalet Partners with OraPharma to Co-Promote SPRIX® Nasal SprayEgalet Partners with OraPharma to Co-Promote SPRIX® Nasal Spray
finance.yahoo.com - January 3 at 8:39 AM
Egalet (EGLT) Rating Lowered to Hold at Stifel NicolausEgalet (EGLT) Rating Lowered to Hold at Stifel Nicolaus
www.americanbankingnews.com - January 3 at 8:22 AM
$8.54 Million in Sales Expected for Egalet Corporation (EGLT) This Quarter$8.54 Million in Sales Expected for Egalet Corporation (EGLT) This Quarter
www.americanbankingnews.com - January 2 at 6:46 PM
ETFs with exposure to Egalet Corp. : December 26, 2017ETFs with exposure to Egalet Corp. : December 26, 2017
finance.yahoo.com - December 28 at 2:40 PM
Contrasting Edge Therapeutics (EDGE) and Egalet (EGLT)Contrasting Edge Therapeutics (EDGE) and Egalet (EGLT)
www.americanbankingnews.com - December 26 at 3:46 AM
EGLT: Debt Refinancing With BenefitsEGLT: Debt Refinancing With Benefits
finance.yahoo.com - December 22 at 9:29 PM
Egalet Corporation (EGLT) Given Average Rating of "Buy" by BrokeragesEgalet Corporation (EGLT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 22 at 6:14 AM
Egalet (EGLT) Announces Refinancing of Existing Convertible Notes - StreetInsider.comEgalet (EGLT) Announces Refinancing of Existing Convertible Notes - StreetInsider.com
www.streetinsider.com - December 21 at 5:22 PM
Egalet Reduces Debt Obligation, Extends Maturity and Lowers Annual Interest Payments through Refinancing of Existing Convertible NotesEgalet Reduces Debt Obligation, Extends Maturity and Lowers Annual Interest Payments through Refinancing of Existing Convertible Notes
finance.yahoo.com - December 20 at 9:31 AM
Egalet Corp (EGLT) Sparks Optimism Among Investors; Here’s WhyEgalet Corp (EGLT) Sparks Optimism Among Investors; Here’s Why
finance.yahoo.com - December 15 at 5:56 PM
Egalet (EGLT) Given a $7.00 Price Target by Cantor Fitzgerald AnalystsEgalet (EGLT) Given a $7.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - December 15 at 12:50 PM
Egalet (EGLT) Granted Tentative FDA Approval for Expanded Label for ARYMO ER (morphine sulfate) C-II - StreetInsider.comEgalet (EGLT) Granted Tentative FDA Approval for Expanded Label for ARYMO ER (morphine sulfate) C-II - StreetInsider.com
www.streetinsider.com - December 15 at 9:53 AM
Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO® ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic PainEgalet Receives FDA Tentative Approval for Expanded Label for ARYMO® ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain
finance.yahoo.com - December 15 at 9:53 AM
Zacks: Brokerages Expect Egalet Corporation (EGLT) to Announce -$0.38 Earnings Per ShareZacks: Brokerages Expect Egalet Corporation (EGLT) to Announce -$0.38 Earnings Per Share
www.americanbankingnews.com - December 14 at 1:16 AM
Egalet (EGLT) Notified by CVS Caremark that SPRIX Nasal Spray Will no Longer be on its FormularyEgalet (EGLT) Notified by CVS Caremark that SPRIX Nasal Spray Will no Longer be on its Formulary
www.streetinsider.com - December 7 at 9:41 AM
Egalet (EGLT) Notified by CVS Caremark that SPRIX Nasal Spray Will no Longer be on its Formulary - StreetInsider.comEgalet (EGLT) Notified by CVS Caremark that SPRIX Nasal Spray Will no Longer be on its Formulary - StreetInsider.com
www.streetinsider.com - December 6 at 5:22 PM
Analyzing Egalet (EGLT) and Halozyme Therapeutics (HALO)Analyzing Egalet (EGLT) and Halozyme Therapeutics (HALO)
www.americanbankingnews.com - December 6 at 3:12 AM
ETFs with exposure to Egalet Corp. : December 5, 2017ETFs with exposure to Egalet Corp. : December 5, 2017
finance.yahoo.com - December 5 at 5:17 PM
Active-Investors: Wired News - Egalet Shares Positive Top-Line Results from Phase-3 Study of Egalet-002 in Patients with Chronic Low Back PainActive-Investors: Wired News - Egalet Shares Positive Top-Line Results from Phase-3 Study of Egalet-002 in Patients with Chronic Low Back Pain
www.finanznachrichten.de - November 30 at 9:58 AM
Wired News – Egalet Shares Positive Top-Line Results from Phase-3 Study of Egalet-002 in Patients with Chronic Low Back PainWired News – Egalet Shares Positive Top-Line Results from Phase-3 Study of Egalet-002 in Patients with Chronic Low Back Pain
finance.yahoo.com - November 30 at 9:58 AM
EARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses MarkEARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses Mark
www.rttnews.com - November 29 at 9:34 AM
Egalet (EGLT) Given a $7.00 Price Target at Cantor FitzgeraldEgalet (EGLT) Given a $7.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - November 28 at 3:36 PM
Zacks: Brokerages Expect Egalet Corporation (EGLT) Will Post Quarterly Sales of $8.54 MillionZacks: Brokerages Expect Egalet Corporation (EGLT) Will Post Quarterly Sales of $8.54 Million
www.americanbankingnews.com - November 28 at 2:08 PM
Egalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back PainEgalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back Pain
finance.yahoo.com - November 28 at 8:51 AM
Egalet Corporation (EGLT) Receives Average Recommendation of "Buy" from BrokeragesEgalet Corporation (EGLT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 27 at 6:20 AM
EGLT: Impressive Prescription Growth; Revenues Should FollowEGLT: Impressive Prescription Growth; Revenues Should Follow
finance.yahoo.com - November 22 at 6:59 PM
Egalet (EGLT) Secures Grant from InnoBooster to Develop a Novel Application of Guardian TechnologyEgalet (EGLT) Secures Grant from InnoBooster to Develop a Novel Application of Guardian Technology
www.streetinsider.com - November 21 at 6:25 PM
Egalet receives a grant from InnoBooster to develop a novel application of Guardian TechnologyEgalet receives a grant from InnoBooster to develop a novel application of Guardian Technology
seekingalpha.com - November 21 at 6:25 PM
Egalet (EGLT) Secures Grant from InnoBooster to Develop a Novel ... - StreetInsider.comEgalet (EGLT) Secures Grant from InnoBooster to Develop a Novel ... - StreetInsider.com
www.streetinsider.com - November 20 at 7:00 PM
ETFs with exposure to Egalet Corp. : November 20, 2017ETFs with exposure to Egalet Corp. : November 20, 2017
finance.yahoo.com - November 20 at 7:00 PM
Egalet Received a Grant from InnoBooster to Develop a Novel Application of Guardian™ TechnologyEgalet Received a Grant from InnoBooster to Develop a Novel Application of Guardian™ Technology
www.prnewswire.com - November 20 at 6:24 AM
Egalet (EGLT) Says Top-Line Results Show Phase 3 Safety Study of Egalet-002 Generally Well-ToleratedEgalet (EGLT) Says Top-Line Results Show Phase 3 Safety Study of Egalet-002 Generally Well-Tolerated
www.streetinsider.com - November 17 at 12:39 PM
Today’s Research Reports on Trending Tickers: Egalet Corporation and Intrexon CorporationToday’s Research Reports on Trending Tickers: Egalet Corporation and Intrexon Corporation
finance.yahoo.com - November 17 at 12:38 PM

SEC Filings

Egalet (NASDAQ:EGLT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Egalet (NASDAQ:EGLT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Egalet (NASDAQ EGLT) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.